{
  "case_id": "EI22-37078",
  "year": 2022,
  "patient_info": {
    "age_range": "11 to 20",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [
    "Antiphospholipid Syndrome",
    "Antiphospholipid Syndrome"
  ],
  "complications": [],
  "symptoms": [
    "joint pain",
    "muscle pain"
  ],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Arthritis Rx",
  "treatments_requested": [
    {
      "name": "Abatacept",
      "drug_type": "experimental",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [
    {
      "name": "Azathioprine",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Mycophenolate Mofetil",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Benlysta",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Anifrolumab",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "is_denial_upheld": true,
  "issues_considered": [
    "medical_necessity",
    "plan_coverage"
  ],
  "other_issues": null,
  "guidelines_support": false,
  "guidelines_not_support": true,
  "guidelines_details": "Orencia is not indicated for the treatment of positive lupus anticoagulant and anticardiolipin. Medical literature shows Orencia failed to meet its primary endpoint in a phase II/III trial for lupus nephritis.",
  "soc_support": false,
  "soc_not_support": true,
  "soc_details": "Standard medications recommended for SLE include azathioprine, CellCept, Benlysta, and Saphnelo, which have been demonstrated to be safe and effective.",
  "study_support": true,
  "study_details": [
    {
      "study_name": "Phase II/III trial for lupus nephritis",
      "study_authors": "Not specified",
      "key_findings": "Orencia failed to meet its primary endpoint, time to complete response."
    }
  ],
  "key_questions": [
    "medical_necessity",
    "plan_coverage"
  ],
  "expedited": true,
  "rationale": "The requested Orencia is not likely to be more beneficial for treatment of the patient\u2019s medical condition than any available standard therapy. The Health Plan\u2019s denial should be upheld.",
  "reviewer_credentials": "Physician reviewers are board certified in internal medicine with subspecialty certification in rheumatology and are actively practicing."
}